1
Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/cg15
2
Type 2 diabetes in adults: management | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ng28
3
Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis. http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf
4
Obesity: identification, assessment and management | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/cg189
5
Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing. https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/
6
NHS Evidence: an introduction. http://www.solent.nhs.uk/_store/documents/nhs_evidence_guide.pdf
7
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
8
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
9
Atkinson MA. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine 2012;2:a007641–a007641. doi:10.1101/cshperspect.a007641
10
Jelinek HF, Stranieri A, Yatsko A, et al. Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. Computers in Biology and Medicine 2016;75:90–7. doi:10.1016/j.compbiomed.2016.05.005
11
S M Attard. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes 2015;5. doi:doi: 10.1038/nutd.2015.16
12
Samuel VT, Shulman GI. Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell 2012;148:852–71. doi:10.1016/j.cell.2012.02.017
13
Beverley M Shields. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open 2015;5. doi:doi: 10.1136/bmjopen-2015-009088
14
Zaccardi F, Webb DR, Yates T, et al. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgraduate Medical Journal 2016;92:63–9. doi:10.1136/postgradmedj-2015-133281
15
Anthony H. Barnett, Jenny Grice. New Mechanisms in Glucose Control. BMJ Books; 1 edition 2013. http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133
16
Gregg EW. The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. Diabetes Care Published Online First: 10 August 2017. doi:10.2337/dci16-0055
17
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
18
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
19
Copeland KC, Silverstein J, Moore KR, et al. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. PEDIATRICS 2013;131:364–82. doi:10.1542/peds.2012-3494
20
Kenneth Hodson. Gestational diabetes: emerging concepts in pathophysiology. Obstetric Medicine 2010;3. doi:doi: 10.1258/om.2010.100025
21
Latika Sahu. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. Obstetric Medicine 2009;2. doi:doi: 10.1258/om.2009.080049
22
Schwartz SS, Epstein S, Corkey BE, et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care 2016;39:179–86. doi:10.2337/dc15-1585
23
Nolan CJ, Ruderman NB, Kahn SE, et al. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes 2015;64:673–86. doi:10.2337/db14-0694
24
Gale EA. Is type 2 diabetes a category error? The Lancet 2013;381:1956–7. doi:10.1016/S0140-6736(12)62207-7
25
Moreno-Castilla C, Mauricio D, Hernandez M. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. Current Diabetes Reports 2016;16. doi:10.1007/s11892-016-0717-7
26
Noctor E, Dunne F. Postnatal testing following gestational diabetes. The Lancet Diabetes & Endocrinology 2015;3:761–2. doi:10.1016/S2213-8587(15)00322-8
27
Birkeland KI. Hyperglycaemia in pregnancy: still a lot to learn. The Lancet Diabetes & Endocrinology 2015;3:752–3. doi:10.1016/S2213-8587(15)00282-X
28
Rinki Murphy. Monogenic diabetes and pregnancy. Obstetric Medicine 2015;8. doi:doi: 10.1177/1753495X15590713
29
Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. New England Journal of Medicine 2016;375:644–54. doi:10.1056/NEJMoa1602494
30
Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3. https://www.nice.org.uk/guidance/ng3
31
Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine 2013;30:803–17. doi:10.1111/dme.12159
32
Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care. http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview
33
Brown J, Alwan NA, West J, et al. Lifestyle interventions for the treatment of women with gestational diabetes. In: Cochrane Database of Systematic Reviews. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD011970.pub2
34
Rasouli B, Andersson T, Carlsson P-O, et al. Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. Diabetic Medicine 2017;34:1259–63. doi:10.1111/dme.13410
35
Davies M, Dahl D, Heise T, et al. Introduction of biosimilar insulins in Europe. Diabetic Medicine 2017;34:1340–53. doi:10.1111/dme.13400
36
Perrin NE, Davies MJ, Robertson N, et al. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. Diabetic Medicine 2017;34:1508–20. doi:10.1111/dme.13448
37
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
38
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
39
Standards of Medical Care in Diabetes--2015: Summary of Revisions. Diabetes Care 2015;38:S4–S4. doi:10.2337/dc15-S003
40
A Randomised trial of the effect and cost-effectiveness of early intensive mulitfactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diaberes:the anglod-Danish-Dutch Study of intensive Treatment in People with Screen-Detected Diabetes in Primary care (ADDITION-Europe) study. http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-64#abstract
41
Kamlesh Khunti. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE 2015;10. doi:doi: 10.1371/journal.pone.0135702
42
Tao L, Wilson ECF, Wareham NJ, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabetic Medicine 2015;32:907–19. doi:10.1111/dme.12711
43
Gray LJ, Khunti K, Wilmot EG, et al. External validation of two diabetes risk scores in a young UK South Asian population. Diabetes Research and Clinical Practice 2014;104:451–8. doi:10.1016/j.diabres.2014.03.018
44
Gray LJ, Khunti K, Edwardson C, et al. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia 2012;55:3238–44. doi:10.1007/s00125-012-2725-8
45
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–9. doi:10.2337/dc14-2441
46
Guidelines. https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes
47
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
48
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
49
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
50
Davies MJ, Heller S, Skinner TC, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008;336:491–5. doi:10.1136/bmj.39474.922025.BE
51
Johnston BC, Kanters S, Bandayrel K, et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. JAMA 2014;312. doi:10.1001/jama.2014.10397
52
Steven S, Hollingsworth KG, Al-Mrabeh A, et al. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care 2016;39:808–15. doi:10.2337/dc15-1942
53
Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. Diabetic Medicine 2015;32:1149–55. doi:10.1111/dme.12722
54
Amy Kennedy. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. PLoS ONE 2013;8. doi:doi: 10.1371/journal.pone.0058861
55
Chimen M, Kennedy A, Nirantharakumar K, et al. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia 2012;55:542–51. doi:10.1007/s00125-011-2403-2
56
Umpierre D. Physical Activity Advice Only or Structured Exercise Training and Association With HbA Levels in Type 2 Diabetes. JAMA 2011;305. doi:10.1001/jama.2011.576
57
Avery L, Flynn D, van Wersch A, et al. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. Diabetes Care 2012;35:2681–9. doi:10.2337/dc11-2452
58
Barry VW, Baruth M, Beets MW, et al. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. Progress in Cardiovascular Diseases 2014;56:382–90. doi:10.1016/j.pcad.2013.09.002
59
Qin L, Knol MJ, Corpeleijn E, et al. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. European Journal of Epidemiology 2010;25:5–12. doi:10.1007/s10654-009-9395-y
60
Lee I-M. Physical Activity and Weight Gain Prevention. JAMA 2010;303. doi:10.1001/jama.2010.312
61
John M Jakicic. Physical activity considerations for the treatment and prevention of obesity. The American Journal of Clinical Nutrition 2005;82:226S-229S.http://ajcn.nutrition.org/content/82/1/226S
62
Heinonen I, Helajärvi H, Pahkala K, et al. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. BMJ Open 2013;3. doi:10.1136/bmjopen-2013-002901
63
Sallis JF, Bull F, Guthold R, et al. Progress in physical activity over the Olympic quadrennium. The Lancet 2016;388:1325–36. doi:10.1016/S0140-6736(16)30581-5
64
Yeh JS, Kushner RF, Schiff GD. Obesity and Management of Weight Loss. New England Journal of Medicine 2016;375:1187–9. doi:10.1056/NEJMclde1515935
65
Henson, Joseph. Associations of Sedentary Time with Fat Distribution in a High-Risk Population. Published Online First: 10 November 2014.https://lra.le.ac.uk/handle/2381/32505
66
The Eatwell Guide. Public Health England 2016. https://www.gov.uk/government/publications/the-eatwell-guide
67
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008. http://www.nice.org.uk/guidance/ta151
68
Hadjiconstantinou M, Byrne J, Bodicoat DH, et al. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. Journal of Medical Internet Research 2016;18. doi:10.2196/jmir.5991
69
Young-Hyman D, de Groot M, Hill-Briggs F, et al. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140. Diabetes Care 2017;40:287.1-287. doi:10.2337/dc17-er02
70
Capehorn M, Polonsky WH, Edelman S, et al. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia ). Diabetic Medicine Published Online First: March 2017. doi:10.1111/dme.13357
71
Hartman YAW, Jansen HJ, Hopman MTE, et al. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. Diabetes Care 2017;40:e120–1. doi:10.2337/dc17-0787
72
Hessler DM, Fisher L, Polonsky WH, et al. Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. Diabetic Medicine 2017;34:1228–34. doi:10.1111/dme.13381
73
Ferrari M, Dal Cin M, Steele M. Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. Diabetic Medicine 2017;34:1546–53. doi:10.1111/dme.13451
74
William H. Polonsky,Lawrence Fisher,Jay Earles,R. James Dudl,Joel Lees,Joseph Mullan. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. Diabetes Carehttp://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true
75
Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357
76
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
77
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
78
Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet 2012;380:475–83. doi:10.1016/S0140-6736(12)60691-6
79
Rizos CV, Kei A, Elisaf MS. The current role of thiazolidinediones in diabetes management. Archives of Toxicology 2016;90:1861–81. doi:10.1007/s00204-016-1737-4
80
Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. New England Journal of Medicine 2007;356:2457–71. doi:10.1056/NEJMoa072761
81
Tanner M. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. Annals of Internal Medicine 2016;165. doi:10.7326/ACPJC-2016-165-4-020
82
Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 2015;109:378–88. doi:10.1016/j.diabres.2015.05.025
83
Bennett WL, Maruthur NM, Singh S, et al. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. Annals of Internal Medicine 2011;154. doi:10.7326/0003-4819-154-9-201105030-00336
84
Merlin C. Thomas. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Therapy 2016;7. doi:doi: 10.1007/s13300-016-0189-4
85
Paul Craddy. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Therapy 2014;5. doi:doi: 10.1007/s13300-014-0061-3
86
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
87
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
88
Ryder B, McKnight J, Blann A, et al. ABCD position statement on GLP-1 based therapies and pancreatic damage. Practical Diabetes 2013;30:388–91. doi:10.1002/pdi.1816
89
Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. JAMA 2007;298. doi:10.1001/jama.298.2.194
90
Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet 2009;374:39–47. doi:10.1016/S0140-6736(09)60659-0
91
Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE. http://www.nice.org.uk/guidance/PH38
92
Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care 2010;33:1255–61. doi:10.2337/dc09-1914
93
Buse JB, Bergenstal RM, Glass LC, et al. Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine 2011;154. doi:10.7326/0003-4819-154-2-201101180-00300
94
Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. The Lancet 2010;375:2223–33. doi:10.1016/S0140-6736(10)60407-2
95
Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet 2010;375:2234–43. doi:10.1016/S0140-6736(10)60406-0
96
Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism 2007;9:194–205. doi:10.1111/j.1463-1326.2006.00704.x
97
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ta390/chapter/1-Recommendations
98
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine Published Online First: 15 September 2016. doi:10.1056/NEJMoa1607141
99
Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The Lancet Diabetes & Endocrinology 2016;4:525–36. doi:10.1016/S2213-8587(15)00482-9
100
Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE. https://www.nice.org.uk/advice/esnm26/chapter/evidence-review
101
Dapagliflozin in combination therapy for treating type 2 diabetes June 2013. http://www.nice.org.uk/guidance/ta288
102
Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015. https://www.nice.org.uk/guidance/ta248
103
Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010. https://www.nice.org.uk/guidance/ta203
104
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 2016;375:311–22. doi:10.1056/NEJMoa1603827
105
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 2016;375:1797–9. doi:10.1056/NEJMc1611289
106
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine 2016;375:323–34. doi:10.1056/NEJMoa1515920
107
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine 2016;375:1799–802. doi:10.1056/NEJMc1611290
108
Courtney H, Nayar R, Rajeswaran C, et al. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017;Volume 10:79–87. doi:10.2147/DMSO.S126763
109
Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 2015;373:232–42. doi:10.1056/NEJMoa1501352
110
Rotz ME, Ganetsky VS, Sen S, et al. Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice 2015;69:531–49. doi:10.1111/ijcp.12572
111
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 2016;375:311–22. doi:10.1056/NEJMoa1603827
112
Levin PA, Nguyen H, Wittbrodt E, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017;Volume 10:123–39. doi:10.2147/DMSO.S130834
113
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
114
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
115
Leff DR, Heath D. Surgery for obesity in adulthood. BMJ 2009;339:b3402–b3402. doi:10.1136/bmj.b3402
116
Schauer PR, Kashyap SR, Wolski K, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. New England Journal of Medicine 2012;366:1567–76. doi:10.1056/NEJMoa1200225
117
Riddle MC, Aronson R, Home P, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36:2489–96. doi:10.2337/dc12-2454
118
Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. New England Journal of Medicine 2004;351:2683–93. doi:10.1056/NEJMoa035622
119
Persaud SJ, Jones PM. A Wake-up Call for Type 2 Diabetes? New England Journal of Medicine 2016;375:1090–2. doi:10.1056/NEJMcibr1607950
120
Fagin JA, Wells SA. Biologic and Clinical Perspectives on Thyroid Cancer. New England Journal of Medicine 2016;375:1054–67. doi:10.1056/NEJMra1501993
121
National Obesity Observatory. http://www.noo.org.uk
122
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine 2017;376:641–51. doi:10.1056/NEJMoa1600869
123
Min SH, Yoon J-H, Hahn S, et al. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes/Metabolism Research and Reviews 2017;33. doi:10.1002/dmrr.2818
124
Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet 2014;384:1349–57. doi:10.1016/S0140-6736(14)60976-4
125
Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–58. doi:10.2337/dc13-2761
126
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine 2017;376:641–51. doi:10.1056/NEJMoa1600869
127
Bethel MA, Engel SS, Green JB, et al. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care 2017;40:494–501. doi:10.2337/dc16-1135
128
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
129
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
130
Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine 2010;363:311–20. doi:10.1056/NEJMoa1002853
131
Choudhary P, Parrott NR, Birtles L, et al. Islet cell transplantation: current status in the UK (2012). Practical Diabetes 2012;29:280–5. doi:10.1002/pdi.1707
132
Pickup JC. Insulin-Pump Therapy for Type 1 Diabetes Mellitus. New England Journal of Medicine 2012;366:1616–24. doi:10.1056/NEJMct1113948
133
Srinivasan P, Huang GC, Amiel SA, et al. Islet cell transplantation. Postgraduate Medical Journal 2007;83:224–9. doi:10.1136/pgmj.2006.053447
134
Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010. https://www.nice.org.uk/guidance/ta203
135
Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine 2017;34:1205–11. doi:10.1111/dme.13379
136
Dhatariya KK, Skedgel C, Fordham R. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. Diabetic Medicine 2017;34:1361–6. doi:10.1111/dme.13427
137
Leelarathna L, Roberts SA, Hindle A, et al. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. Diabetic Medicine 2017;34:1372–9. doi:10.1111/dme.13412
138
Yates T, Davies MJ. Physical activity and Type 1 diabetes: an underused therapy. Diabetic Medicine 2017;34:1498–9. doi:10.1111/dme.13445
139
Narendran P, Jackson N, Daley A, et al. Exercise to preserve β-cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. Diabetic Medicine 2017;34:1521–31. doi:10.1111/dme.13439
140
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
141
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
142
Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. Journal of diabetes science and technology (Online);3.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/
143
Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care 2015;38:1583–91. doi:10.2337/dc15-0279
144
[ARCHIVED CONTENT] Medicines management: Everybody’s business : Department of Health - Publications and statistics. http://webarchive.nationalarchives.gov.uk/20080205132320/http:/dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/dh_082200
145
Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009. https://www.nice.org.uk/guidance/cg76
146
Grammes J, Stock W, Mann CG, et al. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. Diabetic Medicine Published Online First: 30 August 2017. doi:10.1111/dme.13506
147
Sivasubramaniyam S, Amiel SA, Choudhary P. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. Diabetic Medicine 2017;34:1456–60. doi:10.1111/dme.13438
148
Vloemans AF, van Beers CAJ, de Wit M, et al. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. Diabetic Medicine 2017;34:1470–6. doi:10.1111/dme.13429
149
Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes. Diabetes Research and Clinical Practice 2008;82:S118–21. doi:10.1016/j.diabres.2008.09.051
150
Bailey, Stephen. Academic Writing : A Handbook for International Students. http://lib.myilibrary.com.ezproxy4.lib.le.ac.uk/Open.aspx?id=310467
151
Creme P, Lea MR. Writing At University: A Guide For Students. 3rd ed. Maidenhead: : McGraw-Hill Education 2008. https://ebookcentral.proquest.com/lib/leicester/detail.action?pq-origsite=primo&docID=345134
